FDA ANDA · ANDA206791
CISATRACURIUM BESYLATE
Sponsor: SOMERSET THERAPS LLC
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA206791
TYPE
ANDA
ORIGINAL APPROVAL
2019-02-20
LATEST ACTION
2026-10-20
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
CISATRACURIUM BESYLATE PRESERVATIVE FREEPrescription
CISATRACURIUM BESYLATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
CISATRACURIUM BESYLATE PRESERVATIVE FREEPrescription
CISATRACURIUM BESYLATE EQ 10MG BASE/ML · INJECTABLE · INJECTION
Approval history
2026-10-20Labeling · Supplement 9 · standardAP
2020-05-26Labeling · Supplement 2 · standardAP
2019-02-20UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →